IRulya Therapeutics Inc. Common Stock
IRLA
40 hedge funds and large institutions have $8.4M invested in IRulya Therapeutics Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
5% more funds holding
Funds holding: 38 → 40 (+2)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
4.12% less ownership
Funds ownership: 24.75% → 20.62% (-4.1%)
38% less capital invested
Capital invested by funds: $13.5M → $8.4M (-$5.11M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$109K |
| 2 |
Jane Street
New York
|
+$99K |
| 3 |
Mariner
Overland Park,
Kansas
|
+$98K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$74.2K |
| 5 |
Renaissance Technologies
New York
|
+$47.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$2.12M |
| 2 |
KAM
Knightsbridge Asset Management
Newport Beach,
California
|
-$344K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$149K |
| 4 |
Two Sigma Advisers
New York
|
-$77.3K |
| 5 |
Two Sigma Investments
New York
|
-$65.3K |
IRLA Hedge Fund Activity: Q3 2023 in Review
40 of the 6,313 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q3 2023, worth a combined $8.4M — down 38% from $13.5M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IRLA positions and 2 closed out — a net gain of 2 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Bridgeway Capital Management, adding an estimated $109K. The largest seller was BML Capital Management, exiting entirely with an estimated $2.12M sold.
- 40 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q3 2023, up from 38 in Q2 2023.
- Funds reported $8.4M of IRulya Therapeutics Inc. Common Stock stock for Q3 2023, down 38% quarter-over-quarter.
- 4 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q3 2023 and 2 closed out, a net change of +2 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q3 2023 was Bridgeway Capital Management, an estimated $109K added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q3 2023 was BML Capital Management, an estimated $2.12M sold.
Based on aggregated 13F filings for Q3 2023.